Longeveron has completed enrolment for its Phase IIb clinical trial (ELPIS II) evaluating cellular therapy laromestrocel as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS). 

Laromestrocel is a scalable, allogeneic cellular therapy being evaluated in multiple indications. 

Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-months. 

“Completion of enrolment in this pivotal trial is an important step on the pathway to a potential additional treatment for HLHS,” said Nataliya Agafonova, Chief Medical Officer of Longeveron. “Current HLHS treatment requires infants to undergo a complex three-stage surgical reconstruction of their heart over the first three to four years of their life, yet even with this comprehensive treatment, only 50% of infants survive to adolescence due to right ventricular failure.  

“We believe the data generated to date in HLHS support the potential for laromestrocel as a regenerative medical therapy to help these infants and look forward to sharing the data from this clinical trial when it is completed.” 

ELPIS II has enrolled 40 paediatric patients at twelve infant and children’s treatment institutions across the country.  

The trial’s primary endpoint is a composite of survival at 12 months, length of hospitalisation and change in right ventricular ejection fraction measured between baseline and 12 months.  

Children in the Phase I ELPIS trial experienced 100% transplant-free survival up to five years after receiving laromestrocel during the Glenn surgery, compared to an approximate 20% mortality rate observed from historical control data.  

The US Food and Drug Administration (FDA) has granted laromestrocel Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for the treatment of HLHS. 

Diana Turner, Senior Digital Content Editor, DDW